Advancing a novel pipeline addressing large patient populations

Our platform capabilities have generated a pipeline of targeted radiopharmaceutical programs to address unmet needs in prevalent solid tumors.

Pipeline

Program	Target/Indication	Discovery	IND-enabling	Phase 1b	Phase 2/3
	Nectin-4 expressing solid tumors
AKY-1189 was generated using our miniprotein radioconjugate platform and is designed to deliver ²²⁵Ac, a highly potent alpha-emitting radioisotope, to Nectin-4 expressing tumors. Our AKY-1189 program is targeting locally advanced or metastatic UC, breast cancer, NSCLC, colorectal cancer and cervical cancer. Currently in a multi-site Phase 1b study: NCT07020117
	B7-H3 expressing solid tumors
AKY-2519 was generated using our miniprotein radioconjugate platform and is designed to deliver ²²⁵Ac, a highly potent alpha-emitting radioisotope, to B7-H3 CD276 expressing tumors. Our AKY-2519 program is targeting prostate, lung and other solid tumors. Currently in IND-enabling studies.
Multiple Programs	Undisclosed
	Undisclosed

Posters & Publications

10/25/2024

Oral Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024 titled, “AKY-1189, a novel, ﬁrst-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors.”

READ MORE

10/25/2024

Poster Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024 titled, “Discovery and pre-clinical development of AKY-1189, a potent and selective Nectin-4 miniprotein binder optimized for use as a targeted radiopharmaceutical.”

READ MORE

10/25/2024

Poster Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024 titled, “Allometric scaling of preclinical dosimetry for the Nectin-4 miniprotein binders AKY-807 and AKY-1189 accurately predicts human absorbed dose to major organs.”

READ MORE

Partner with us

Interested in bringing alpha radiotherapy to the mainstream? Contact us for information about corporate partnership opportunities.

Scientist in lab coat holding a test tube and beaker